The use of Enterprise stent in treating symptomatic intracranial atherosclerotic stenosis : follow-up observation results
10.3969/j.issn.1008-794X.2019.03.002
- VernacularTitle:Enterprise支架治疗症状性颅内动脉粥样硬化性狭窄随访结果
- Author:
Yanhua DONG
1
;
Chao LIU
;
Haowen XU
;
Xinbin GUO
;
Sheng GUAN
Author Information
1. 郑州大学第一附属医院神经介入科 450052
- Keywords:
Enterprise stent;
symptomatic intracranial atherosclerotic stenosis;
endovascular treatment
- From:
Journal of Interventional Radiology
2019;28(3):217-221
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of the use of Enterprise stent in the treatment of symptomatic intracranial atherosclerotic stenosis (sICAS) . Methods The clinical data of 27 patients with sICAS, who were treated with Enterprise stent implantation at First Affiliated Hospital of Zhengzhou University, China, during the period from January 2012 to December 2017, were retrospectively collected. The patient's basic parameters, characteristics of target lesions, technical success rate, perioperative safety and follow-up results were analyzed. Results A total of 27 patients (28 lesions in total) were enrolled in this study, and a total of 28 Enterprise stents were implanted. The preoperative mean stenosis degree of lesions was (75.7 ±6.7) ％, the postoperative residual stenosis degree was (23.2 ±16.6) ％. The technical success rate was 100％. Postoperative complication of perforating branch events occurred in 2 patients. No severe complications such as hemorrhage, artery dissection, in-stent thrombosis, hyper-perfusion syndrome, or cardiovascular events occurred. All patients were followed up for (10.8±9.1) months, and 3 instent restenosis lesions (≥50％) were detected although the patients had no target lesion-related symptoms, the incidence of in-stent restenosis was 10.7％. No newly-developed stroke caused by responsible blood vessel, bleeding events or death occurred. Conclusion For the treatment of sICAS, balloon dilatation followed by Enterprise stent implantation is technically feasible, and clinically safe and effective. The incidence of perioperative complications is low and the follow-up results are satisfactory. Further randomized controlled trials are still needed before its long-term efficacy is clarified.
